Personal Information. Language Skills. Address. Telephone. Email. Language Read Write Speak Understand English Yes Yes Yes Yes French Yes Yes Yes Yes



Similar documents
SHORT CLINICAL GUIDELINE SCOPE

Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief

Diagnosis, classification and prevention of diabetes

Diabetes mellitus. Lecture Outline

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

Introduction. Pathogenesis of type 2 diabetes

Diabetes is a. A case for prevention of type 2 diabetes mellitus

Telephone:

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Type II diabetes: How to use the new oral medications

Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference

Present and Future of Insulin Therapy: Research Rationale for New Insulins

David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Diabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW

Cardiovascular Disease in Diabetes

Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007

Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides.

INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?

IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL

Overview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus

Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes

DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study

Diabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Cardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005

Harmony Clinical Trial Medical Media Factsheet

COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL

Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine. Graduate Certificate. Metabolic & Nutritional Medicine

Effects of macronutrients on insulin resistance and insulin requirements

Prior Authorization Guideline

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Improving drug prescription in elderly diabetic patients. FRANCESC FORMIGA Hospital Universitari de Bellvitge

Baskets of Care Diabetes Subcommittee

Practical Applications of Insulin Pump Therapy in Type 2 Diabetes

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours

DM Management in Elderly- What are the glucose targets?

Diabetes Medications: Insulin Therapy

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)

Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

Jill Malcolm, Karen Moir

New in Diabetes. Diabetes is becoming more common. By the. What s. Presented at McMaster University, Hamilton, Ontario, October 2001.

Insulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust

Insulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types

Pathophysiology of Type 2 Diabetes and Its Treatment Policy

THE STUDY OF NEWLY DISCOVERED CASES OF DIABETES MELLITUS IN BIHOR COUNTY

Improving primary care management of depression in adults with comorbid chronic illnesses

Intensive Insulin Therapy in Diabetes Management

Trends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins

Abdulaziz Al-Subaie. Anfal Al-Shalwi

Deakin Research Online

NCT sanofi-aventis HOE901_3507. insulin glargine

PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.

linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd

WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES. Living your life as normal as possible

Nutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT

In many diabetes units, people with type

Britni Hebert, MD PGY-1

Glycemic Control of Type 2 Diabetes Mellitus

Treatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections.

Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children

How To Prevent Type 2 Diabetes

Type 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment. Bruce Latham, M.D. Endocrine Specialists Greenville Health System

Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Support Supplement

Type 2 Diabetes. Tabinda Dugal GP Day 4/05/16

Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care

Tunis_2012-CCP lecture

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME

trends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-

Cardiovascular Effects of Drugs to Treat Diabetes

Synthesis of ECT evidence

I. Research Proposal. 1. Background

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities

Guidelines for the management of hypertension in patients with diabetes mellitus

Type 2 Diabetes in Youth A Road Less Travelled

Quick Reference Guide

Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks

NOUVELLLES THERAPIES EN DIABÈTE

Insulin switch & Algorithms Rotorua GP CME June Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB

Curriculum Vitae Eric S. Miguelino, M.D. Staff Toxicologist, Department of Public Health, Food and Drug Branch, State of California

DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES

Cochrane Quality and Productivity topics

Department Of Biochemistry. Subject: Diabetes Mellitus. Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage.

HEALTH CLAIMS ON PECTINS APPROVED BY EFSA

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

ETIOLOGIC CLASSIFICATION. Type I diabetes Type II diabetes

Resumen Curricular de los Profesores. Jesse Boehm

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment

Management of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)

THE PATHOPHYSIOLOGIC BASIS FOR DIABETES TREATMENT: EVALUATING THE EFFECT OF INCRETIN-BASED THERAPIES * Jack Leahy, MD

EFFICIENT HEALTH SERVICE CORRIDORS FOR THE DIAGNOSIS AND TREATMENT OF WOMEN WITH BREAST CANCER

Type 2 Diabetes workshop notes

Transcription:

Protected when completed This is a draft version only. Do not submit to any funding organization. Only the final version from the History page can be submitted. It is strictly forbidden to submit this draft version to an organization that is not a member of the CCV. The complete list of CCV members is available at www.ccv-cvc.ca Personal Information Identification Correspondence language: English Sex: Male Date of Birth: 8/25 Canadian Residency Status: Canadian Citizen Country of Citizenship: Canada Language Skills Language Read Write Speak Understand English Yes Yes Yes Yes French Yes Yes Yes Yes Address The primary address is denoted by (*) Courier Primary Affiliation (*) CRCHUM Hôtel-Dieu 3850 St. Urbain Street Masson Pavilion, Rm 8-202 Montréal H2W 1T7 Canada, Quebec CRCHUM Hôtel-Dieu 3850 St. Urbain Street Masson Pavilion, Rm 8-202 Montréal H2W 1T7 Canada, Quebec Telephone The primary telephone is denoted by (*) Fax 514-4127208 Work 514-8908000 extension: 12923 Work (*) 514-8908000 extension: 12732 Email The primary email is denoted by (*) Work (*) jean.louis.chiasson@umontreal.ca 1

User Profile DRAFT Disciplines Trained In: Endocrinology Research Disciplines: Endocrinology Areas of Research: Diabetes, Hormonal Regulation, Metabolism, Nutrition, Pharmacoepidemiology Fields of Application: Biomedical Aspects of Human Health, Pathogenesis and Treatment of Diseases Research Specialization Keywords: carbohydrate metabolism, complications, diabetes melllitus, glucagon secretion/action, glucose turnover, insulin secretion/action, isotopic technique, nutrition/ treatment, organ perfusion, prevention Education Degrees 1970/7-1975/7 Diploma - Certification - Endocrinology - McGill University - Completed 1967/7-1968/7 Doctorate - LMCC - M.D. - Endocrinologist - Medical Research Council of Canada - Completed 1963/9-1967/7 Doctorate - M.D. - Medical Doctor - Université Laval - Completed 1961/9-1963/7 Bachelor's - B.A. - Chemistry - Sainte-Anne - Completed Employment Academic Work Experience 1992/10 - Chief, Research Group on Diabetes and Metabolic Regulation CRCHUM 1992/7 - Full Professor Université de Montréal - Médecine 1980/7 - Endocrinologist CHUM Affiliations The primary affiliation is denoted by (*) (*) 1992/7 - Full Professor - Médecine - Université de Montréal Research Funding History Awarded 2012/5-2019/5 The effect of dulaglutide on major cardiovascular events in patients with type 2 diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND). : Jean-Louis Chiasson 2

2012/6-2017/6 2011/4-2016/4 2010/1-2015/1 2012/5-2014/5 2011/7-2013/7 DRAFT 2012/5-2019/5 Clinical randomized trial Eli Lilly Canada Inc. Total Funding: 266220 (Canadian dollar) Determinants of increased risk of cardio-vascular diseases in HIV-infected individuals. 2012/6-2017/6 Subvention d'équipe: VIH/sida et comorbidités Canadian Institutes of Health Research (CIHR) Total Funding: 497945 (Canadian dollar) Étude de phase IV multicentrique, à répartition aléatoire et à double insu avec contrôle par placebo visant à évaluer l effet de la saxagliptine sur l incidence du décès d origine cardiovasculaire, de l infarctus du myocarde ou de l AVC ischémique.. Co-investigator : Sophie Bernard 2011/4-2016/4 AstraZeneca Canada Inc. Total Funding: 187500 (Canadian dollar) TECOS: A randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with sitagliptin in patients with type 2 diabetes mellitus and inadequate glycemic control on mono- or dual combination on oral... : Chiasson, Jean-Louis;Étude multicentrique; 2009/11-2015/11 Clinical trial Merck & Co. Inc Total Funding: 320000 (Canadian dollar) The impact of LY2605541 versus insulin glargine for patients with type 1 diabetes mellitus treated with preprandial insulin lispro: a double-blind, randomized, 52-week study. The IMAGINE 3 Study. Co-investigator : Sophie Bernard 2012/5-2014/5 Clinical randomized trial Eli Lilly Canada Inc. Total Funding: 141552 (Canadian dollar) A 24-week, multicenter, international, randomized (1:1), parallel-group, openlabel, comparative study of insulin glargine versus liraglutide in insulin-naive patients with type 2 diabetes trated with oral agents and not adequately controlled with... Co-investigator : Sophie Bernard 3

2012/7-2013/6 Applicant 2012/5-2013/5 2010/3-2013/3 2011/2-2013/2 2011/4-2012/4 DRAFT 2011/7-2013/7 Sanofi-aventis Total Funding: 53450 (Canadian dollar) Quelle est l'évidence justifiant la recommandation d'utiliser 1 mg de glucagon pour corriger l'hyperglycémie sévère chez le sujet avec diabète de type 1? Applicant : Jean-Louis Chiasson 2012/7-2013/6 Diabetes Québec Total Funding: 20000 (Canadian dollar) 6-month, multicenter, randomized, open-label, parallel-group study comparing the efficacy and safety of a new formulation of insulin glargine and Lantus both plus mealtime insulin in patients with type 2 diabetes mellitus with a 6-mo safety extension Co-investigator : Sophie Bernard 2012/5-2013/5 Clinical randomized trial Sanofi-aventis Total Funding: 58536 (Canadian dollar) Autogestion du diabète et dépression : Marie-Dominique Beaulieu 2010/3-2013/3 Operating grant Canadian Institutes of Health Research (CIHR) Total Funding: 232883 (Canadian dollar) A randomized, doule-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of canagliflozin compared with placebo in the treatment of older subjects with type 2 diabetes mellitus inadequately.. Co-investigator : Sophie Bernard 2011/2-2013/2 Clinical trial, Janssen Inc. Janssen-Ortho Inc. Total Funding: 94918 (Canadian dollar) A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 mg and 25 mg once daily) and sitagliptin (100 mg once daily) given for a minimum of 76 weeks (incl. 24 weeks of preceding trial)... Co-investigator : Sophie Bernard 4

2010/1-2011/1 DRAFT 2011/4-2012/6 Clinical trial, Boehringer Ingelheim Boehringer Ingelheim Total Funding: 52814 (Canadian dollar) VIH et prévention des comorbidités: Adapter et valider une intervention virtuelle visant à réduire les facteurs de risque liés aux maladies cardiovasculaires et au diabète chez les personnes vivant avec le VIH. : Josée Coté 2010/1-2011/1 Operating grant Canadian Institutes of Health Research (CIHR) Total Funding: 99956 (Canadian dollar) Completed 2011/1-2012/1 2007/7-2011/7 2010/9-2011/3 2010/1-2011/1 A randomized trial evaluating the effect of liraglutide versus insulin glargine on hepatic steatosis as measured by MRI and MRS in metformin-treated patients with type 2 diabetes. : An Tang 2010/1-2011/1 RSNA R&E Foundation Fonds de la Recherche en Santé du Québec (FRSQ) Total Funding: 47500 (Canadian dollar) Rigorous evaluation and integration medicine in aboriginal diabetes care. : Pierre Haddad 2007/7-2011/7 Team in Traditional Aboriginal Plants Against Diabetes Canadian Institutes of Health Research (CIHR) Total Funding: 850000 (Canadian dollar) A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 24 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control. Co-investigator : Sophie Bernard 2010/9-2011/3 Clinical trial, Boehringer Ingelheim Boehringer Ingelheim Total Funding: 52814 (Canadian dollar) Essai randomisé du liraglutide versus l'insuline glargine sur la stéatose hépatique... : An Tang 5

2010/1-2011/1 2007/7-2010/7 2009/1-2010/1 2007/7-2009/7 2007/6-2008/12 DRAFT 2010/1-2011/1 Diabetes Québec Total Funding: 20000 (Canadian dollar) Essai randomisé du liraglutide versus l'insuline glargine sur la stéatose hépatique mesurée par résonance magnétique chez les patients atteints de diabète de type 2 traités à la metformine. : Tang, An;Dr Jean-Louis Chiasson 2010/1-2011/1 Canadian Heads of Academic Radiology (CHAR) Total Funding: 7500 (Canadian dollar) Estimating the prevalence of diabetes using multiple tests: A validation of the national diabetes surveillance system definition. : Elham Rahme 2007/7-2010/7 INMD Diabetes Surveillance Systems/CIHR Canadian Institutes of Health Research (CIHR) Total Funding: 299999 (Canadian dollar) Innovation in cardiovascular imaging and image-guided therapy to improve patient management. : Gilles Soulez 2009/1-2010/1 FCI 20974 Canada Foundation for Innovation (CFI) Total Funding: 1199774 (Canadian dollar) The DREAM On Study (an observational study). Diabetes REduction Assessment with ramipril and rosiglitazone Medication Ongoing evaluation. : Hertzel C. Gerstein 2007/7-2008/7 Clinical Trial Canadian Institutes of Health Research (CIHR) Total Funding: 13500 (Canadian dollar) A multicenter, randomized, double-blind study to evaluate the safety and efficacy of the addition of sitagliptin (MK-0431) to patients with type 2 diabetes mellitus who have inadequate glycemic control on insulin therapy (alone or in combination... Co-investigator : Rémi Rabasa-Lhoret 2007/6-2008/12 Merck Frosst Canada Inc Total Funding: 52312 (Canadian dollar) 6

2007/11-2008/11 A 12-week, randomized, multicenter, double-blind, placebo-controlled study, assessing the safety and efficacy of ID1101 in obese patients Co-investigator : Rémi Rabasa-Lhoret 2007/11-2008/11 Innodia Inc. Total Funding: 62520 (Canadian dollar) Activities Supervisory Activities Student/Postdoctoral Supervision Co-Supervisor Supervisor Co-Supervisor Co-Supervisor Supervisor Supervisor Sima Aurelia - Doctorate - Université de Montréal - In Progress Student Degree Start Date: 2009/1 Student Degree Expected Date: 2013/6 Project Description: L acide rétinoïque dans l obésité et le diabète de type 2 Present Position: Ph.D. Student Lorena Iglesias - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2009/1 Student Degree Received Date: 2011/6 Project Description: Évaluation d'un prototype d'un détecteur de glucose photonique. Present Position: public sector Constantin Manolescu Daniel - Doctorate - Université de Montréal - In Progress Student Degree Start Date: 2009/1 Student Degree Expected Date: 2013/6 Project Description: Retinoic acid and insulin resistance in the development of type 2 diabetes Present Position: Ph.D. Student Janie Houle, - Post-doctorate - UQAM - Completed Student Degree Start Date: 2007/1 Student Degree Received Date: 2011/12 Project Description: Impact de la dépression sur les comportements d'autogestion du diabète Present Position: academic sector Zebdi Samia - Bachelor's - UQTR - Completed Student Degree Start Date: 2007/1 Student Degree Received Date: 2007/4 Project Description: Le rôle de l'hyperglycémie post-prandiale dans les complications coronariennes Brindisi Marie-Claude - Post-doctorate - CHU Bocage (Dijon, France) - Completed Student Degree Start Date: 2004/12 Student Degree Received Date: 2007/4 Project Description: Effets de l'acarbose et du répaglinide sur le stress oxydatif... Present Position: Endocrinologist, Dijon (France) 7

Supervisor Supervisor Co-Supervisor Supervisor Supervisor Geneviève Beauregard, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2003/1 Student Degree Received Date: 2005/1 Project Description: Étude de la régulation de l'expression des gènes par l'insuline et le glucose Demiana Ekladous, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2003/1 Student Degree Received Date: 2005/6 Project Description: Hepatic resistance to glucagon Amélie Pelletier, - Doctorate - Université de Montréal - Completed Student Degree Start Date: 2000/6 Student Degree Received Date: 2006/6 Project Description: Regulation of glucose uptake in cardiomyocytes Present Position: Research Coordinator Sandra Bérubé, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2000/6 Student Degree Received Date: 2003/7 Project Description: Insulin sensitivity in a healthy population Present Position: private sector Yamina Boukhors, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 1998/9 Student Degree Received Date: 2003/8 Project Description: Use of information technology for management of ITT in type 1 diabetes Present Position: other International Collaboration Activities 2008-01-01 - Member Contributions Presentations United Kingdom Activity Description: The Acarbose Cardiovascular Evaluation (ACE) Trial 2013-09-28 "Prevention of diabetes: Are we there yet?", At the Heart of Diabetes. An Essential Primer for Cardiovascular Renal and Metabolic Risk Reduction in Diabetes., Canada, Ontario, Toronto Invited?: Yes 2013-09-25 Vincent Poitout, "La glucotoxicité et la lipotoxicité dans le développement du diabète de type 2 et des complications vasculaires : approches fondamentales et cliniques.", Séminaire de la direction scientifique, Département de médecine, CHUM, Canada, Quebec, Montreal Invited?: Yes 8

2013-04-19 "Lignes directrices de pratique clinique pour la prévention et le traitement du diabète 2013", Endocrine Grand Round, Division of Endocrinology, CHUM, Canada, Quebec, Montreal Invited?: Yes 2013-03-29 "Pré-diabète: fault-il le traiter?", Congrès de la Société Francophone du diaète 2013, France, Montpellier Invited?: Yes 2013-02-05 "Treatment of diaetes mellitus and the vascular complications.", SANOFI Guest speaker, Canada, Quebec, Laval Invited?: Yes 2012-11-29 "Treating postprandial hyperglycaemia for the prevention of cardiovascular disease.", National Atherosclerosis and Cardiometabolic Forum, Canada, Ontario, Toronto Invited?: Yes 2012-11-13 "Les complications vasculaires du diabète de type 2: peut-on les freiner?", Eli Lilly Guest Speaker, Canada, Quebec, Montreal Invited?: Yes 2012-10-26 "Mieux traiter les troubles métaboliques des patients VIH en 2012.", Dépistage et gestion du diabète chez le patient VIH, Canada, Quebec, Montréal Invited?: Yes 2012-07-13 "Treating postprandial plasma glucose for the prevention of diabetes and CVD: the STOP-NIDDM Trial.", Bayer Scientific Meeting., China, Beijing : Bayer HealthCare AG - 0 2012-04-14 "La glycémie postprandiale et le risque cardiovasculaire.", Bayer Scientific Symposium, Tunisia, Djerba : Bayer AG - 0 2012-04-13 "Le rôle des incrétines dans le diabète de type 2.", 21e Congrès National d'endocrinologie de la Société Tunisienne d'endocrinologie, Diabète et Maladies Métaboliques, Tunisia, Tunis : Bayer AG - 0 2012-04-13 "Le traitement de l'hyperglycémie postprandiale pour la prévention du diabète et des complications cardiovasculaires.", 21e Congrès National d'endocrinologie de la Société Tunisienne d'endocrinologie, Diabète et Maladies Métaboliques, Tunisia, Tunis : Bayer AG - 0 9

2012-04-12 "La glycémie et le risque cardiovasculaire.", Bayer Guest Speaker, Tunisia, Tunis : Bayer AG - 0 2012-04-11 "La glycémie postprandiale et le risque cardiovasculaire.", Bayer Guest Speaker, Tunisia, Sfax : Bayer AG - 0 2011-12-05 "Disposition index and the conversion of IGT to diabetes mellitus: The STOP- NIDDM Trial.", International Diabetes Federation 2011 (IDF 2011). Session: Insulin resistance in young and old., United Arab Emirates, Dubai 2011-08-26 "Le rôle de la microflore intestinale dans le développement de l'obésité.", Guest Speaker Sanofi, Scientific Grand Round, Division of Endocrinology, CHUM, Canada, Quebec, Montréal 2011-07-19 "Glucose control and cardiovascular disease.", ACE Regional Meeting, Speaker Tour, China, Guangzhou 2011-07-17 "Glucose control and cardiovascular disease.", ACE Regional Meeting, Speaker Tour., China, Hangzhou 2011-06-02 "Traiter l'hyperglycémie postprandiale pour la prévention du diabète et des complications vasculaires.", Sanofi Aventis Guest speaker, Division of Endocrinology, Montreal Jewish Hospital., Canada, Quebec, Montreal 2011-05-05 "Traiter l'hyperglycémie postprandiale pour diminuer le risque de diabète et de ses complications vasculaires.", Bayer Workshop., France, Nice 2011-03-05 "How to achieve safe and long-term glycaemic control with cardiovascular benefits.", Bayer Schering Pharma, 2nd Cardiovascular Risk Management Symposium. The Challenge of Cardiovascular Disease Prevention., France, Nice 2010-05-30 "CSN Debate: Hemoglobin A1C should be normalized with intensive insulin therapy to prevent macro- and microvascular disease in type 2 diabetes. Affirmative: Jean-Louis Chiasson, Negative: Richard Gilbert", Canadian Society of Nephrology Annual General Meeting 2010., Canada, Quebec, Montreal 2010-05-15 "L'hyperglycémie post-prandiale, son rôle délétère et sa prise en charge.", Congrès annuel de la Société Algérienne de Diabétologie., Algeria, Alger 2010-05-15 "La prévention du diabète de type 2.", Congrès annuel de la Société Algérienne de Diabétologie., Algeria, Alger 10

11 2010-05-08 "Evidence for CV benefits with acarbose intervention.", Bayer Schering Pharma Asia-Pacific Cardiovascular Risk Management Expert Workshop., Taiwan, Province of China, Taipei 2010-05-07 "Effects of oral diabetic drugs on CVD.", Bayer Schering Pharma Asia-Pacific ACE Speaker. Training Workshop., Taiwan, Province of China, Taipei 2010-04-22 "Atteindre les cibles en diabète: Nouvelles options pour l'insulinothérapie.", Sanofi Aventis Guest Speaker. Division of Endocrinology, Montreal Jewish Hospital., Canada, Quebec, Montreal 2009-10-20 "Guest speaker and Chairman: Intervention multifactorielle dans le traitement du diabète de type 2.", Optimizing long-term glycemic control in type 2 diabetes: Overcoming a progressive pathophysiology with incretin therapie (WorldWIDE), Symposium during the 20th IDF World Diabetes Congress., Canada, Quebec, Montreal 2009-10-20 "Debate on Primary prevention programmes for diabetes: lifestyle versus drugs - Drugs.", 20th IDF World Diabetes Congress., Canada, Quebec, Montreal 2009-10-18 "Guest speaker and Chairman. Glucose lowering interventions in diabetes and CVD - lessons from outcome studies.", Bayer Healthcare Satellite Symposium, 20th IDF World Diabetes Congress, Canada, Quebec, Montreal 2009-10-18 "Traiter l'hyperglycémie postprandiale pour diminuer le risque de diabète et de ses complications vasculaires.", Bayer Healthcare Meet the Expert Session, 20th IDF World Diabetes Congress., Canada, Quebec, Montreal 2009-10-08 "Postprandial peak reduction and its implication in the prevention of CV risk and diabetes.", Congress of Obesity, Metabolic Syndrome and Prediabetes., Venezuela, Bolivarian Republic of, Caracas 2009-05-29 "La prévention du diabète de type 2 et de ses complications.", Guest speaker Eli Lilly, Division of Endocrinology., Canada, New Brunswick, Moncton 2009-04-24 "Stratégies de sensibilisation à l'insuline et d'apport d'insuline dans le traitement du diabète de type 2. Quand et pourquoi?", Diabetes Forum., Canada, Quebec, Montreal 2009-02-28 "Postprandial plasma glucose as a risk factor for cardiovascular disease.", Endocrine Grand Round, Division of Endocrinology, University of Toronto., Canada, Ontario, Toronto 2009-02-27 "The benefits of early insulin as opposed to oral hypoglycemic agents in type 2 diabetes.", Canadian Society of Endocrinology and Metabolism., Canada, Ontario, Toronto

2009-02-26 "L'insulinothérapie : Initiation pratique et nouvelles insulines.", SSVQ Symposium (Société des sciences vasculaires du Québec) - Le diabète: démystifier l'insulinothérapie et les nouveaux hypoglycémiants oraux., Canada, Quebec, Montreal Interviews and Media Relations Broadcast Interviews 2013-01-15-2013-01-15 Publications PubMed Articles Type 2 diabetes "Les docteurs" - Radio-Canada Chiasson JL, "Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.", Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 12 Suppl 1 PubMed ID: 16627376 2013-06-04 Althouse AD, Abbott JD, Sutton-Tyrrell K, Forker AD, Lombardero MS, Buitrón LV, Pena-Sing I, Tardif JC, Mori Brooks M,, "Favorable Effects of Insulin Sensitizers Pertinent to Peripheral Arterial Disease in Type 2 Diabetes: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.", Diabetes care PubMed ID: 23735723 2013-05-08 Leong A, Dasgupta K, Chiasson JL, Rahme E, "Estimating the Population Prevalence of Diagnosed and Undiagnosed Diabetes.", Diabetes care PubMed ID: 23656982 2013-04-30 Tamis-Holland JE, Lu J, Korytkowski M, Magee M, Rogers WJ, Lopes N, Mighton L, Jacobs AK,, "Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revasc", Journal of the American College of Cardiology, 61(17) PubMed ID: 23500245 2013-04-16 Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, Bertolet M, Mathewkutty S, Teo K, Maron DJ, Sethi SS, Domanski M, Frye RL, Fuster V, "Risk factor control for coronary artery disease secondary prevention in large randomized trials.", Journal of the American College of Cardiology, 61(15) PubMed ID: 23500281 2013-03-07 Ismail-Beigi F, Lombardero MS, Escobedo J, Genuth S, Green J, Massaro E, Mooradian AD, Ovalle F, Whitehouse F, Zonszein J,, "Determinants of successful glycemic control among participants in the BARI 2D Trial: A Post-hoc Analysis.", Journal of diabetes and its complications PubMed ID: 23478173 12

2013-01-01 Wolever, T.M.S., Gibbs, A.L., Chiasson, J.L., Connelly, P.W., Josse, R.G., Leiter, L.A., Maheux, P., Rabasa-Lhoret, R., Rodger, N.W., Ryan, E.A., "Altering source or amount of dietary carbohydrate has acute and chronic effects on postprandial glucose and triglycerides in type 2 diabetes: Canadian trial of Carbohydrates in Diabetes (CCD).", Nutr. Metab. Cardiovasc. Dis., 23 PubMed ID: 22397878 2012-12-20 Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S, Bertrand M, Fuster V,, "Strategies for multivessel revascularization in patients with diabetes.", The New England journal of medicine, 367(25) PubMed ID: 23121323 2012-12-01 Bergenstal RM, Forti A, Chiasson JL, Woloschak M, Boldrin M, Balena R, "Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial).", Diabetes therapy : research, treatment and education of diabetes and related disorders, 3(1) PubMed ID: 23138449 2012-07-01 Hanefeld M, Pistrosch F, Koehler C, Chiasson JL, "Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial.", Journal of hypertension, 30(7) PubMed ID: 22573126 2012-03-23 Henderson M, Baillargeon JP, Rabasa-Lhoret R, Chiasson JL, Hanley J, Lambert M, "Estimating insulin secretion in youth using simple indices derived from the oral glucose tolerance test.", Diabetes & metabolism PubMed ID: 22445514 2012-03-05 Wolever TM, Gibbs AL, Chiasson JL, Connelly PW, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW, Ryan EA, "Altering source or amount of dietary carbohydrate has acute and chronic effects on postprandial glucose and triglycerides in type 2 diabetes: Canadian trial of Carbohydrates in Diabetes (CCD).", Nutrition, metabolism, and cardiovascular diseases : NMCD PubMed ID: 22397878 2011-12-01 Broderick TL, El Midaoui A, Chiasson JL, Wang D, Jankowski M, Gutkowska J, "The effects of exercise training on #-butyrobetaine hydroxylase and novel organic cation transporter-2 gene expression in the rat.", Applied physiology, nutrition, and metabolism = Physiologie appliquée, nutrition et métabolisme, 36(6) PubMed ID: 22014179 2011-06-01 "Incidence of diabetes following ramipril or rosiglitazone withdrawal.", Diabetes care, 34(6) PubMed ID: 21515846 2011-03-01 Gerstein HC, Mohan V, Avezum A, Bergenstal RM, Chiasson JL, Garrido M, MacKinnon I, Rao PV, Zinman B, Jung H, Joldersma L, Bosch J, Yusuf S, "Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.", Diabetologia, 54(3) PubMed ID: 21116607 13

2011-02-01 Singh PP, Abbott JD, Lombardero MS, Sutton-Tyrrell K, Woodhead G, Venkitachalam L, Tsapatsaris NP, Piemonte TC, Lago RM, Rutter MK, Nesto RW,, "The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.", Diabetes care, 34(2) PubMed ID: 21270200 2011-02-01 Henderson M, Rabasa-Lhoret R, Bastard JP, Chiasson JL, Baillargeon JP, Hanley JA, Lambert M, "Measuring insulin sensitivity in youth: How do the different indices compare with the gold-standard method?", Diabetes & Metabolism, 37(1) PubMed ID: 21126900 2010-02-01 Tuomilehto J, Lindström J, Hellmich M, Lehmacher W, Westermeier T, Evers T, Brückner A, Peltonen M, Qiao Q, Chiasson JL, "Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-the STOP-NIDDM riskscore.", Diabetes research and clinical practice, 87(2) PubMed ID: 20022651 2009-11-01 Chiasson JL, "Early insulin use in type 2 diabetes: what are the cons?", Diabetes care, 32 Suppl 2 PubMed ID: 19875563 2009-11-01 de Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil C, Pillai A, Cooper M, Grobbee DE, Hackett M, Hamet P, Heller SR, Lisheng L, Macmahon S, Mancia G, Neal B, Pan CY, Patel A, Poulter N, Travert F, Woodward M,, "Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.", Diabetologia, 52(11) PubMed ID: 19688336 2009-11-01 Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, Woodward M, Chalmers J,, Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F, "Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.", Diabetes care, 32(11) PubMed ID: 19651921 2009-06-11 Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE, "A randomized trial of therapies for type 2 diabetes and coronary artery disease.", The New England journal of medicine, 360(24) PubMed ID: 19502645 2009-03-01 Hammana I, Coderre L, Potvin S, Costa M, Berthiaume Y, Lavoie A, Chiasson JL, Levy E, Rabasa-Lhoret R, "Dichotomy between postprandial glucose and lipid profiles in adults with cystic fibrosis: a pilot study.", Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 8(2) PubMed ID: 19083274 14

2009-03-01 Pop-Busui R, Lu J, Lopes N, Jones TL,, "Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.", Journal of the peripheral nervous system : JPNS, 14(1) PubMed ID: 19335534 2009-01-01 Hanefeld M, Karasik A, Koehler C, Westermeier T, Chiasson JL, "Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.", Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease, 6(1) PubMed ID: 19156626 2008-12-01 Sreenan S, Virkamäki A, Zhang K, Hansen JB,, "Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.", International journal of clinical practice, 62(12) PubMed ID: 19166444 2008-12-01 Godbout A, Hammana I, Potvin S, Mainville D, Rakel A, Berthiaume Y, Chiasson JL, Coderre L, Rabasa-Lhoret R, "No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes.", Diabetes & metabolism, 34(6 Pt 1) PubMed ID: 18922724 2008-09-01 Wolever TM, Mehling C, Chiasson JL, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW, Ryan EA, "Low glycaemic index diet and disposition index in type 2 diabetes (the Canadian trial of carbohydrates in diabetes): a randomised controlled trial.", Diabetologia, 51(9) PubMed ID: 18648764 2008-09-01 "Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.", American heart journal, 156(3) PubMed ID: 18760137 2008-08-01 Ekladous D, Mehdi MZ, Costa M, Srivastava AK, Chiasson JL, Coderre L, "Tissue- and fibre-specific modifications of insulin-signalling molecules in cardiac and skeletal muscle of diabetic rats.", Clinical and experimental pharmacology & physiology, 35(8) PubMed ID: 18430054 2008-07-01 Cloutier G, Zimmer A, Yu FT, Chiasson JL, "Increased shear rate resistance and fastest kinetics of erythrocyte aggregation in diabetes measured with ultrasound.", Diabetes care, 31(7) PubMed ID: 18375419 2008-06-12 Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F, "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.", The New England journal of medicine, 358(24) PubMed ID: 18539916 15

2008-05-01 Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S, "Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.", Diabetes care, 31(5) PubMed ID: 18268075 2008-01-01 Wolever TM, Gibbs AL, Mehling C, Chiasson JL, Connelly PW, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW, Ryan EA, "The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of lowglycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein.", The American journal of clinical nutrition, 87(1) PubMed ID: 18175744 2007-12-01 Chiasson JL, "Prevention of Type 2 diabetes: fact or fiction?", Expert opinion on pharmacotherapy, 8(18) PubMed ID: 18035959 2007-11-30 Costa M, Potvin S, Hammana I, Malet A, Berthiaume Y, Jeanneret A, Lavoie A, Lévesque R, Perrier J, Poisson D, Karelis AD, Chiasson JL, Rabasa- Lhoret R, "Increased glucose excursion in cystic fibrosis and its association with a worse clinical status.", Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 6(6) PubMed ID: 17409029 2007-10-01 Godbout A, Chiasson JL, "Who should benefit from the use of alphaglucosidase inhibitors?", Current diabetes reports, 7(5) PubMed ID: 18173965 2007-09-08 Patel A,, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B, "Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.", Lancet, 370(9590) PubMed ID: 17765963 2007-09-01 Fontaine-Bisson B, Wolever TM, Chiasson JL, Rabasa-Lhoret R, Maheux P, Josse RG, Leiter LA, Rodger NW, Ryan EA, Connelly PW, Corey PN, El-Sohemy A, "Genetic polymorphisms of tumor necrosis factor-alpha modify the association between dietary polyunsaturated fatty acids and fasting HDLcholesterol and apo A-I concentrations.", The American journal of clinical nutrition, 86(3) PubMed ID: 17823444 2007-06-01 Hammana I, Malet A, Costa M, Brochiero E, Berthiaume Y, Potvin S, Chiasson JL, Coderre L, Rabasa-Lhoret R, "Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis.", Diabetes & metabolism, 33(3) PubMed ID: 17418606 16

2007-06-01 Chui MH, Papanikolaou Y, Fontaine-Bisson B, Turcotte J, Wolever TM, El- Sohemy A, Chiasson JL, Rabasa-Lhoret R, Maheux P, Ryan E, Greenwood CE, "The TNF-alpha-238G > a single-nucleotide polymorphism protects against memory decline in older adults with type 2 diabetes.", Behavioral neuroscience, 121(3) PubMed ID: 17592954 2007-05-01 Fontaine-Bisson B, Wolever TM, Chiasson JL, Rabasa-Lhoret R, Maheux P, Josse RG, Leiter LA, Rodger NW, Ryan EA, El-Sohemy A, "Tumor necrosis factor alpha -238G>A genotype alters postprandial plasma levels of free fatty acids in obese individuals with type 2 diabetes mellitus.", Metabolism: clinical and experimental, 56(5) PubMed ID: 17445540 2007-04-01 Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M,, "Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.", Diabetes, 56(4) PubMed ID: 17317762 2007-04-01 Meugnier E, Faraj M, Rome S, Beauregard G, Michaut A, Pelloux V, Chiasson JL, Laville M, Clement K, Vidal H, Rabasa-Lhoret R, "Acute hyperglycemia induces a global downregulation of gene expression in adipose tissue and skeletal muscle of healthy subjects.", Diabetes, 56(4) PubMed ID: 17303805 2007-02-01 Pelletier A, Tardif A, Gingras MH, Chiasson JL, Coderre L, "Chronic exposure to ketone bodies impairs glucose uptake in adult cardiomyocytes in response to insulin but not vanadate: the role of PI3-K.", Molecular and cellular biochemistry, 296(1-2) PubMed ID: 16960657 2007-01-01 Brindisi MC, Hahn J, Chiasson JL, Rabasa-Lhoret R, "Under-utilization of capillary glucose monitoring by type 2 diabetic patients.", Diabetes research and clinical practice, 75(1) PubMed ID: 16814897 2006-10-12 Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR, "Effect of ramipril on the incidence of diabetes.", The New England journal of medicine, 355(15) PubMed ID: 16980380 2006-09-23 Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR, "Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.", Lancet, 368(9541) PubMed ID: 16997664 2006-08-01 Andrulionyte L, Laukkanen O, Chiasson JL, Laakso M,, "Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial.", Journal of molecular medicine (Berlin, Germany), 84(8) PubMed ID: 16838170 17

2006-07-01 Andrulionyte L, Peltola P, Chiasson JL, Laakso M,, "Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.", Diabetes, 55(7) PubMed ID: 16804087 2006-06-19 Sobel BE,, "Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial: Synergies and opportunities.", The American journal of cardiology, 97(12A) PubMed ID: 16813738 2006-06-19 Albu J, Gottlieb SH, August P, Nesto RW, Orchard TJ,, "Modifications of coronary risk factors.", The American journal of cardiology, 97(12A) PubMed ID: 16813737 2006-06-19 Barsness GW, Gersh BJ, Brooks MM, Frye RL,, "Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.", The American journal of cardiology, 97(12A) PubMed ID: 16813736 2006-06-19 Steiner G,, "Statement of the problem.", The American journal of cardiology, 97(12A) PubMed ID: 16813733 2006-06-19 Magee MF, Isley WL,, "Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.", The American journal of cardiology, 97(12A) PubMed ID: 16813735 2006-06-19 Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, Kelsey SF, Orchard TJ,, "Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.", The American journal of cardiology, 97(12A) PubMed ID: 16813734 2006-06-19 Hlatky MA, Melsop KA, Boothroyd DB,, "Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease.", The American journal of cardiology, 97(12A) PubMed ID: 16813739 2006-04-13 Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J,, "Homocysteine lowering with folic acid and B vitamins in vascular disease.", The New England journal of medicine, 354(15) PubMed ID: 16531613 2006-04-01 Brindisi MC, Rabasa-Lhoret R, Chiasson JL, "Postprandial hyperglycaemia: to treat or not to treat?", Diabetes & metabolism, 32(2) PubMed ID: 16735958 2006-02-01 El Midaoui A, Chiasson JL, Tancrède G, Nadeau A, "Physical training reverses the increased activity of the hepatic ketone body synthesis pathway in chronically diabetic rats.", American journal of physiology. Endocrinology and metabolism, 290(2) PubMed ID: 16403781 18

2006-01-01 Lonn E, Held C, Arnold JM, Probstfield J, McQueen M, Micks M, Pogue J, Sheridan P, Bosch J, Genest J, Yusuf S,, "Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial.", The Canadian journal of cardiology, 22(1) PubMed ID: 16450017 Journal Articles 2011/1 Published First Listed Author 2008/ Published Co-Author 2008/ Published Co-Author 2006/ Published First Listed Author Chiasson, J.L. and Bernard, S., "Reducing cardiovascular risk factors in patients with pre-diabetes.", Diabetes Management, 1, 423-438 Ur, E., Chiasson, J.L., Ransom, T., Rowe, R., "Screening for type 1 and type 2 diabetes.", Can. J. Diabetes, 32(Suppl 1), S14-S16 Ur, E., Chiasson, J.L., Ransom, T., Rowe, R., "Prevention of diabetes.", Can. J. Diabetes, 32(Suppl 1), S17-S19 Chiasson, J.L., "Pharmacological and surgical intervention for the prevention of diabetes.", Nestlé Nutrition Workshop Ser. Clin. Perform. Programme, 11, 31-42 Book Chapters 2012/ In Press First Listed Author 2012/ In Press Last Author "Decreasing postprandial plasma glucose in subjects with IGT using an # (alpha)-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: The STOP-NIDDM Trial.", Prevention of type 2 diabetes; From Science to Therapies, LeRoith, D., Ed., Springer Science Authors: Chiasson, J.L., Laakso, M., and Hanefeld, M.: "Prevention of type 2 diabetes (chapter 38).", Diabetes in America, NIH Authors: Knowler, B., Chiasson, J.L. Clinical Care Guidelines 2012-04-03 "2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada" Description / Contribution Value: The purpose of this review was to determine that there was no salient information missing, no conflicting recommendations, and that the recommendations are generally applicable to clinical practice. 19